We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

On October 31, Bristol-Myers Squibb (NYSE:BMY) released financial results for the third quarter of 2024, which not only beat ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...

On Thursday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $58.5 which represents a slight increase of $0.09 or 0.15% from the prior close of $58.41. The stock opened at ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.